These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28593532)

  • 21. EQ-5D-3L derived population norms for health related quality of life in Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    PLoS One; 2014; 9(11):e108434. PubMed ID: 25365171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
    Kiadaliri AA; Eliasson B; Gerdtham UG
    Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L.
    Lindkvist M; Feldman I
    Health Qual Life Outcomes; 2016 Sep; 14(1):134. PubMed ID: 27644119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
    Stevens K; Brazier J; Rowen D
    Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
    Yfantopoulos J; Chantzaras A; Kontodimas S
    Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating health-related quality of life impact of chronic conditions among older adults from a rural town in Suzhou, China.
    Pan CW; Cong XL; Zhou HJ; Wang XZ; Sun HP; Xu Y; Wang P
    Arch Gerontol Geriatr; 2018; 76():6-11. PubMed ID: 29407731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishing utility values for the 22-item Sino-Nasal Outcome Test (SNOT-22) using a crosswalk to the EuroQol-five-dimensional questionnaire-three-level version (EQ-5D-3L).
    Crump RT; Lai E; Liu G; Janjua A; Sutherland JM
    Int Forum Allergy Rhinol; 2017 May; 7(5):480-487. PubMed ID: 28182331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?
    Ara R; Hill H; Lloyd A; Woods HB; Brazier J
    Value Health; 2020 Mar; 23(3):397-405. PubMed ID: 32197736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.
    Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P
    Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.
    Jiao B; Basu A; Ramsey S; Roth J; Bender MA; Quach D; Devine B
    Value Health; 2022 Feb; 25(2):276-287. PubMed ID: 35094801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health Utility of Pregnant Women Living with HIV/AIDS: Prevention of Mother-to-Child Transmission of HIV (PMTCT) Programs in Yunnan Province: A Cross-Sectional Study.
    Wang X; Guo G; Liang X; Zhou L; Zheng J; Li S; Luo H; Yang Y; Yang L; Tan T; Yu J; Lu L
    Value Health Reg Issues; 2018 May; 15():27-33. PubMed ID: 29474175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSON´S DISEASE POPULATION SAMPLE.
    Garcia-Gordillo MÁ; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellan-Perpiñan JM; Sanchez-Martinez FI
    Nutr Hosp; 2015 Dec; 32(6):2808-21. PubMed ID: 26667738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults.
    Ferreira LN; Ferreira PL; Ribeiro FP; Pereira LN
    Health Qual Life Outcomes; 2016 Jun; 14():89. PubMed ID: 27267761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.
    Shiroiwa T; Fukuda T; Ikeda S; Igarashi A; Noto S; Saito S; Shimozuma K
    Qual Life Res; 2016 Mar; 25(3):707-19. PubMed ID: 26303761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes.
    Sullivan PW; Ghushchyan VH; Campbell JD; Globe G; Bender B; Magid DJ
    Qual Life Res; 2016 Dec; 25(12):3017-3026. PubMed ID: 27387417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
    Thompson NR; Lapin BR; Katzan IL
    Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.